The InspectIR COVID-19 Breathalyzer test can be performed by trained operators in physicians’ offices, hospitals and mobile testing sites, according to an FDA news release. It uses a technique called chromatography gas mass-spectrometry to separate and identify chemical mixtures to quickly detect five compounds associated with a COVID-19 infection in exhaled breath. The device used to analyze results is about the size of a piece of carry-on luggage and can analyze about 160 samples per day.
The test’s performance was validated in a study of 2,409 people with and without symptoms. It displayed a 91.2 percent sensitivity, reflecting the percent of positive samples the test correctly identified, and 99.3 percent specificity, the percent of negative samples the test correctly identified.
InspectIR said it expects to produce 100 machines per week.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
